Caribou Biosciences, Inc. Lease, Cost
Caribou Biosciences, Inc. (CRBU) reported Lease, Cost of $7.91 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-03-05
- Caribou Biosciences, Inc. lease, cost for the quarter ending 2024-12-31 was $1.92M, a 1.13% decline year-over-year.
- Caribou Biosciences, Inc. lease, cost for the quarter ending 2024-09-30 was $2.01M, a 0.65% increase year-over-year.
- Caribou Biosciences, Inc. lease, cost for the quarter ending 2024-06-30 was $1.98M, a 0.45% decline year-over-year.
- Caribou Biosciences, Inc. lease, cost for the quarter ending 2024-03-31 was $2.02M, a 3.54% increase year-over-year.
- Caribou Biosciences, Inc. lease, cost for fiscal 2025 was $7.91M, a 0.30% decline from fiscal 2024.
- Caribou Biosciences, Inc. lease, cost for fiscal 2024 was $7.93M, a 0.65% increase from fiscal 2023.
- Caribou Biosciences, Inc. lease, cost for fiscal 2023 was $7.88M, a 6.17% increase from fiscal 2022.
- Caribou Biosciences, Inc. lease, cost for fiscal 2022 was $7.42M.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $7.91M 10-K · filed 2026-03-05 | |||
| 2024-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.93M derived: sum of 2 quarters · filed 2026-03-05 | $5.91M derived: sum of 3 quarters · filed 2026-03-05 | $7.93M 10-K · filed 2026-03-05 |
| 2024-09-30 | $2.01M 10-Q · filed 2024-11-06 | $3.99M derived: sum of 2 quarters · filed 2024-11-06 | $6.01M 10-Q · filed 2024-11-06 | $7.95M derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-06-30 | $1.98M 10-Q · filed 2024-08-06 | $4.00M 10-Q · filed 2024-08-06 | $5.94M derived: sum of 3 quarters · filed 2025-03-10 | $7.94M derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-03-31 | $2.02M 10-Q · filed 2024-05-07 | $3.96M derived: sum of 2 quarters · filed 2025-03-10 | $5.96M derived: sum of 3 quarters · filed 2025-03-10 | $7.95M derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-12-31 | $1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $3.94M derived: sum of 2 quarters · filed 2025-03-10 | $5.93M derived: sum of 3 quarters · filed 2025-03-10 | $7.88M 10-K · filed 2025-03-10 |
| 2023-09-30 | $2.00M 10-Q · filed 2024-11-06 | $3.99M derived: sum of 2 quarters · filed 2024-11-06 | $5.94M 10-Q · filed 2024-11-06 | $7.83M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $1.99M 10-Q · filed 2024-08-06 | $3.94M 10-Q · filed 2024-08-06 | $5.83M derived: sum of 3 quarters · filed 2024-08-06 | $7.65M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.95M 10-Q · filed 2024-05-07 | $3.84M derived: sum of 2 quarters · filed 2024-05-07 | $5.66M derived: sum of 3 quarters · filed 2024-05-07 | $7.50M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $3.72M derived: sum of 2 quarters · filed 2024-03-11 | $5.56M derived: sum of 3 quarters · filed 2024-03-11 | $7.42M 10-K · filed 2024-03-11 |
| 2022-09-30 | $1.82M 10-Q · filed 2023-11-07 | $3.66M derived: sum of 2 quarters · filed 2023-11-07 | $5.53M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $1.84M 10-Q · filed 2023-08-08 | $3.70M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $1.86M 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |